CYP7A1 and metabolic syndrome: This family has been identified as actively participating in dyslipidemia pathophysiology in patients with coronary artery disease (CAD) [16], as well as in the process of steatosis in hepatic cells, specifically through miR-17, which regulates the expression of CYP7A1 (cytochrome P450 family 7 subfamily A member 1) and is a regulator of hepatic lipid metabolism [17].